Central Alerting System
View Alert

Originator: DHSC & NHS England and Improvement: Supply disruption alert

Issue date: 02-Aug-2021 15:35:33

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Specialists Trusts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Social Care Providers (registered with CAS)
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Mental Health & Learning Disabilities Trusts
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Acute Trusts
  • Community Trusts
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • DHSC Supply Disruption - Medicines
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: Glipizide (Minodiab) 5mg tablets - Supply disruption

Broadcast content: Glipizide 5mg tablets are out of stock until mid-October 2021.
  • Prescribers will need to review all affected patients and assess ongoing need for glipizide. 
  • If ongoing treatment is required, consideration should be given to prescribing an alternative sulfonylurea or glucose lowering medication. 
  • Alternative glucose-lowering medications, including sulfonylureas, remain available. 
  • Patients with monogenic diabetes (MODY) should remain on an equivalent dose of an alternative sulfonylurea.
  • Unlicensed supplies of glipizide 5mg tablets have been sourced and may be considered where the above options are inappropriate. 

This alert contains further information and action for providers.

Please note that no response is required via the CAS website to this alert.

Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy.

Alert reference: SDA/2021/009


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency